Ionis Pharmaceuticals(IONS) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Ionis reports second quarter 2025 financial results and highlights progress on key programs - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis' second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 - - Increasing 2025 financial guidance based on strong performance and improved outlook ...